Pharmacokinetic and pharmacodynamic evaluation of tigecycline

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 11, 2011, Pages 1459-1470

  Giamarellou, Helen ^a   Poulakou, Garyphallia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acinetobacter baumannii; Bacteremia; Klebsiella pneumoniae; KPC; MDR Gram negative bacteria; Off label use; Pneumonia; VAP; VIM; XDR Gram negative bacteria

Indexed keywords

AZTREONAM; CARBAPENEMASE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; IMIPENEM; MEROPENEM; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; AREA UNDER THE CURVE; BACTEREMIA; COMMUNITY ACQUIRED PNEUMONIA; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EVALUATION; HEADACHE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NAUSEA; NONHUMAN; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VOMITING;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GLYCYLGLYCINE; HUMANS; INTRAABDOMINAL INFECTIONS; MINOCYCLINE; PNEUMONIA;

ACINETOBACTER BAUMANNII; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

EID: 80054762740     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.623126     Document Type: Review

References (75)

1. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections. What are the treatment options? Drugs 2009;69:1879-901
2. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5):S303-14 (Pubitemid 41170378)
3. Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis 2007;59:347-9 (Pubitemid 350016698)
4. Kasbekar N. Tigecycline: a new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006;63:1235-43 (Pubitemid 44025089)
5. Letter to Wyeth Pharmaceuticals, Inc. Department of Health & Human Services. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/ appletter/2009/021821s013,021821s017,021821s018ltr. pdf [Accessed 17 May 2011]
6. Questions and answers on the withdrawal of the application for a change to the marketing authorization for tygacil. EMEA. Doc. Ref. EMEA/245771/2008 Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/tygacil/ 24577108en.pdf [Accessed 17 May 2011]
7. Tygacil: for the withdrawal of type II variation application linked to an extension of indication for a medicinal product already authorized in the European Union. EMEA. Withdrawal of variation application EMEA/H/C/644/II/13 for community acquired pneumonia. 2008. Available from: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/tygacil/withdrawalletter.pdf [Accessed 17 May 2011]
8. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008;46:1121-2 (Pubitemid 351589881)
9. Cercenado E, Cercenado S, Gomez JA, et al. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides. J Antimicrob Chemother 2003;52:138-9
10. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-13 (Pubitemid 44527540)
11. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001;40:173-7 (Pubitemid 32913448)
12. Milatovic D, Schmitz FJ, Verhoef J, et al. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400-4 (Pubitemid 36070396)
13. Souli M, Kontopidou FV, Koratzanis E, et al. In vitro activity of tigecycline against multiple-drug resistant, including pan-resistant, Gram-negative and Gram-positive, clinical isolates form Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-9 (Pubitemid 44396429)
14. Bouchillon SK, Iredell JR, Barkham T, et al. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents 2009;33:130-6
15. Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among Gram-negative and Gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clin Ther 2008;30:2040-50
16. BSAC methods for antimicrobial susceptibility testing, Version 7.1, February 2008. BSAC, British Society for Antimicrobial Chemoptherapy. Available from: http://www.bsac.org.uk/-db/-documents/version-7-1-february-2008. pdf [Assessed 19 May 2011]
17. Castanheira M, Sader HS, Deshpande LM, et al. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2008;52:570-3 (Pubitemid 351170830)
18. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80 (Pubitemid 41264122)
19. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000;16:61-3 (Pubitemid 30665426)
20. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46:3164-7
21. Dean CR, Visalli MA, Projan SJ, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8 (Pubitemid 36254223)
22. Performance standards for antimicrobial susceptibility tests: approved standard M100-S21. 21st edition. Clinical and Laboratory Standards Institute. CLSI; Wayne (PA): 2011
23. Tetracyclines-EUCAST clinical MIC breakpoints: tigecycline. Available from: http://www.srga.org/eucastwt/MICTAB/MICtetracyclines.htm [Assessed 19 May 2011]
24. Jones RN, Ferraro MJ, Reller LB, et al. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007;45:227-30 (Pubitemid 46106432)
25. Moland ES, Craft DW, Hong SG, et al. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 2008;52:2940-2
26. Vouillamoz J, Moreillon P, Giddey M, et al. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J Antimicrob Chemother 2008;61:371-4
27. Scheetz MH, Qi C, Warren JR, et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:1621-6 (Pubitemid 46744136)
28. Sands M, McCarter Y, Sanchez W. Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 2007;26:521-2 (Pubitemid 47025046)
29. Available from: www.drugbank.ca/drugs/DB00560 [Accessed 28 August 2011]
30. Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006;58:256-65 (Pubitemid 44294934)
31. Hoffman M, DeMaio W, Jordan RA, et al. Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects. Drug Metab Dispos 2007;35:1543-53 (Pubitemid 47296047)
32. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9 (Pubitemid 40065796)
33. Meagher AK, Ambrose PG, Grasela TH, et al. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71 (Pubitemid 41133541)
34. Muralidharan G, Fruncillo RJ, Micalizzi M, et al. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-9 (Pubitemid 40463415)
35. Meagher A, Cirincione B, Piedmonte M, et al. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment [abstract1023]. Clin Microbiol Infect 2004;10(Suppl 3):274
36. Darling IM, Cirincione BB, Owens JS. Non-compartmental pharmacokinetics of tigecycline in Phase 3 studies of patients with complicated skin and skin structure and intra abdominal infections [abstract A-20]. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; Washington, DC, USA; 2005. p. 17
37. Korth-Bradley JM, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis. J Clin Pharmacol 2011;51:93-10
38. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37:840-51
39. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9 (Pubitemid 44884142)
40. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32 (Pubitemid 40463407)
41. Bulik CC, Wiskirchen DE, Shepard A, et al. Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010;54:5209-13
42. Burkhardt O, Rauch K, Kaever V, et al. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009;34:101-2
43. Conte JE Jr, Golden JA, Kelly MG, et al. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9 (Pubitemid 40732607)
44. Pichardo C, Pachon-Ibanez ME, Docobo-Perez F, et al. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 2010;29:527-31
45. Rubino CM, Forrest A, Bhavnani SM, et al. Tigecycline population pharmacokinetics in patients with community-or hospital-acquired pneumonia. Antimicrob Agents Chemother 2010;54:5180-6
46. Tombs NL, Chaudary I, Conant R, et al. Tissue distribution of Gar-936, a broad-spectrum antibiotic, in male rats [abstract 39]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology; San Francisco, CA, USA; 1999. p. 302
47. Ji AJ, Saunders JP, Amorusi P, et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 2008;48:866-75
48. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003;17:579-98 (Pubitemid 38029154)
49. Petersen PJ, Labthavikul P, Jones CH, et al. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57:573-6 (Pubitemid 43240214)
50. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517-23 (Pubitemid 35429946)
51. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9 (Pubitemid 30165274)
52. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003;47:216-22 (Pubitemid 36070367)
53. Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007;51:1939-45 (Pubitemid 46903077)
54. Ambrose PG, Meagher AK, Passarell JA, et al. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009;63:155-9
55. Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008;52:204-10
56. Ambrose PG, Meagher AK, Passarell JA, et al. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline- Enterobacteriaceae susceptibility breakpoints. Diagn Microbiol Infect Dis 2009;63:38-42
57. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. Surg Infect (Larchmt) 2008;9:57-66 (Pubitemid 351440535)
58. Crandon JL, Kim A, Nicolau DP. Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother 2009;64:837-9
59. Koomanachai P, Crandon JL, Banevicius MA, et al. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 2009;53:5060-3
60. Wiskirchen DE, Koomanachai P, Nicasio AM, et al. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011;55:1420-7
61. Nicasio AM, Crandon JL, Nicolau DP. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:2756-61
62. Ong CT, Babalola CP, Nightingale CH, et al. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005;56:498-501 (Pubitemid 41264126)
63. Dandache P, Nicolau DP, Sakoulas G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Pract 2009;17:66-8
64. Giamarellou H. Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents 2010;36(Suppl 2):S50-4
65. Freire AT, Melnyk V, Kim MJ, et al; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-51
66. Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010;67:180-4
67. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31 (Pubitemid 46017915)
68. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80
69. Garcia-Cabrera E, Jimenez-Mejias ME, Gil Navarro MV, et al. Superinfection during treatment of nosocomial infections with tigecycline. Eur J Clin Microbiol Infect Dis 2010;29:867-71
70. Frampton JE, Curran MP. Tigecycline. Drugs 2005;65:2623-35 (Pubitemid 43049957)
71. Chen LY, Chen TC, Chen YH, et al. Microbial isolation and emergence of antimicrobial resistance associated with tigecycline usage. J Microbiol Immunol Infect 2011;doi:10.1016/j.jmii.2011.01.033
72. Cui JC, Liu YN, Chen LA. Mutant prevention concentration of tigecycline for carbapenem-susceptible and-resistant Acinetobacter baumannii. J Antibiot (Tokyo) 2010;63:29-31
73. Parsonage M, Shah S, Moss P, et al. Breakthrough bacteraemia with a susceptible Enterococcus faecalis during tigecycline monotherapy. J Antimicrob Chemother 2010;65:370-4
74. Poulakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58:273-84
75. Principe L, D'Arezzo S, Capone A, Petrosillo N. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 2009;8:18